Rheumatology

Autoimmune rheumatic diseases have been linked to a higher risk of Long COVID, with certain therapies and clinical factors also linked.

Treat-to-target therapy in early rheumatoid arthritis has been associated with favourable long-term clinical, structural and functional outcomes.

A non-invasive optical imaging method has been associated with skin fibrosis in systemic sclerosis, supporting its use as an outcome measure.

Early diagnosis of axial spondyloarthritis has been associated with less long-term spinal structural damage in a Swiss registry cohort.

A prospective study found higher pregnancy complication rates in women with lupus who were not in remission, particularly among high-risk patients.

Peresolimab has been linked to fewer PD-1 high-expressing CD4 T cells and neutrophils, and reduced inflammatory signalling in rheumatoid arthritis.

Plasma protein signatures have been associated with high structural damage in ankylosing spondylitis, with potential to complement imaging assessment.

Rituximab, mycophenolate mofetil, and cyclophosphamide strategies have shown no significant differences in 52-week outcomes in SLE with lupus nephritis.